Disease risk app can predict your chance of developing dementia

Interested in knowing your chances of getting dementia? An app can now tell you.

Smartphone app Quealth has been clinically validated for its dementia risk assessment feature, which lets users know their chance of developing the neurological disease.

The free app, available in the App Store and Google Play Store, allows anyone to assess their risk of developing common lifestyle-driven diseases like dementia, cardiovascular disease, diabetes, chronic obstructive pulmonary disease and six forms of cancer, according to a statement from the company. Now, it also can predict the risk of someone developing dementia.

"Quealth's risk algorithm has been optimized and validated to an excellent level of predictive accuracy for dementia" said Paul Nash, Quealth's head of clinical governance, in a statement. "It has a 72 percent chance of distinguishing individuals at risk of developing dementia from those who are not at risk.”

Katherine Davis,

Senior Writer

As a Senior Writer for TriMed Media Group, Katherine primarily focuses on producing news stories, Q&As and features for Cardiovascular Business. She reports on several facets of the cardiology industry, including emerging technology, new clinical trials and findings, and quality initiatives among providers. She is based out of TriMed's Chicago office and holds a bachelor's degree in journalism from Columbia College Chicago. Her work has appeared in Modern Healthcare, Crain's Chicago Business and The Detroit News. She joined TriMed in 2016.

Around the web

CMS finalized a significant policy change when it increased the Medicare payments hospitals receive for performing CCTA exams. What, exactly, does the update mean for cardiologists, billing specialists and other hospital employees?

Stryker, a global medtech company based out of Michigan, has kicked off 2025 with a bit of excitement. The company says Inari’s peripheral vascular portfolio is highly complementary to its own neurovascular portfolio.

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.